The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 24, 2026
Filed:
Jun. 10, 2020
Applicants:
Neurocrine Biosciences, Inc., San Diego, CA (US);
Sanofi, Paris, FR;
Inventors:
Andrew Becker, San Diego, CA (US);
Scott Stirn, San Diego, CA (US);
Joel Radisson, Paris, FR;
Christina Marie Costa, San Diego, CA (US);
Assignees:
Neurocrine Biosciences, Inc., San Diego, CA (US);
Sanofi, Paris, FR;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/426 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); C07D 277/42 (2006.01);
U.S. Cl.
CPC ...
A61K 31/426 (2013.01); A61K 9/0095 (2013.01); A61K 9/107 (2013.01); A61K 9/28 (2013.01); A61K 9/4833 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); C07D 277/42 (2013.01); C07B 2200/13 (2013.01);
Abstract
The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).